• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将利益相关者参与置于美国卫生技术评估的卫生经济模型的核心位置。

Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.

作者信息

Xie Richard Z, Malik Erica deFur, Linthicum Mark T, Bright Jennifer L

机构信息

Innovation and Value Initiative, Alexandria, Virginia, USA.

出版信息

Pharmacoeconomics. 2021 Jun;39(6):631-638. doi: 10.1007/s40273-021-01036-3. Epub 2021 May 13.

DOI:10.1007/s40273-021-01036-3
PMID:33982198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8166701/
Abstract

While evidence generated from health economic (HE) models is being used more commonly in health technology assessment (HTA) in the US, it is not consistently adopted by different stakeholder groups or across therapeutic areas. We hypothesize that actively engaging with multiple stakeholder groups throughout the model development process may result in models more widely considered by decision makers. To test this hypothesis, the Innovation and Value Initiative has launched a modeling effort to build an open-source HE model focusing on the disease state 'major depressive disorder'. A 20-member advisory group has been formed with representatives from patients, employers, clinicians, innovators, payers, and researchers to guide the model development process. While this effort is still in the early stages, the ongoing stakeholder engagement effort has yielded valuable insights that inform the model design. We have also identified several challenges to implementing this new approach. Our early findings suggest that the stakeholder engagement approach to HE model development has the potential to improve HTA in the US.

摘要

虽然在美国,卫生经济(HE)模型产生的证据在卫生技术评估(HTA)中越来越普遍地被使用,但不同利益相关者群体或不同治疗领域并未一致采用。我们假设,在整个模型开发过程中积极与多个利益相关者群体互动,可能会使模型得到决策者更广泛的考虑。为了验证这一假设,创新与价值倡议组织发起了一项建模工作,以构建一个专注于“重度抑郁症”疾病状态的开源卫生经济模型。一个由20名成员组成的咨询小组已经成立,成员包括患者、雇主、临床医生、创新者、支付方和研究人员的代表,以指导模型开发过程。虽然这项工作仍处于早期阶段,但正在进行的利益相关者参与工作已经产生了为模型设计提供信息的宝贵见解。我们还确定了实施这种新方法的几个挑战。我们的早期研究结果表明,卫生经济模型开发的利益相关者参与方法有可能改善美国的卫生技术评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ec/8166701/e8e1293ff330/40273_2021_1036_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ec/8166701/e8e1293ff330/40273_2021_1036_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7ec/8166701/e8e1293ff330/40273_2021_1036_Fig1_HTML.jpg

相似文献

1
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.将利益相关者参与置于美国卫生技术评估的卫生经济模型的核心位置。
Pharmacoeconomics. 2021 Jun;39(6):631-638. doi: 10.1007/s40273-021-01036-3. Epub 2021 May 13.
2
CONTRIBUTION OF STAKEHOLDER ENGAGEMENT TO THE IMPACT OF A HEALTH TECHNOLOGY ASSESSMENT: AN IRISH CASE STUDY.利益相关方参与对卫生技术评估影响的贡献:爱尔兰案例研究。
Int J Technol Assess Health Care. 2017 Jan;33(4):424-429. doi: 10.1017/S026646231700085X. Epub 2017 Oct 16.
3
Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.利益相关者参与经济评估:使用名义小组技术在嵌合抗原受体 T 细胞治疗的早期经济评估模型开发中征集患者、医疗保健提供者和卫生系统利益相关者意见的方案。
BMJ Open. 2021 Aug 12;11(8):e046707. doi: 10.1136/bmjopen-2020-046707.
4
CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?不断变化的卫生技术评估范式?
Int J Technol Assess Health Care. 2016 Jan;32(4):191-199. doi: 10.1017/S0266462316000386. Epub 2016 Oct 21.
5
The Use of MCDA in HTA: Great Potential, but More Effort Needed.多准则决策分析在卫生技术评估中的应用:潜力巨大,但仍需努力。
Value Health. 2018 Apr;21(4):394-397. doi: 10.1016/j.jval.2017.10.001. Epub 2017 Nov 22.
6
STAKEHOLDER INVOLVEMENT THROUGHOUT HEALTH TECHNOLOGY ASSESSMENT: AN EXAMPLE FROM PALLIATIVE CARE.利益相关者全程参与卫生技术评估:姑息治疗实例。
Int J Technol Assess Health Care. 2017 Jan;33(5):552-561. doi: 10.1017/S026646231700068X. Epub 2017 Sep 4.
7
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders.关于在创新过程中整合早期卫生技术评估:来自五个利益相关者的思考。
Int J Technol Assess Health Care. 2020 Oct;36(5):481-485. doi: 10.1017/S0266462320000756. Epub 2020 Oct 28.
8
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.患者在医疗产品生命周期中的偏好:利益相关者的想法是什么?欧洲和美国的半结构化定性访谈。
Patient. 2019 Oct;12(5):513-526. doi: 10.1007/s40271-019-00367-w.
9
The ethical challenges and opportunities of implementing engagement strategies in health research.实施健康研究参与策略的伦理挑战与机遇。
Ann Epidemiol. 2021 Jul;59:37-43. doi: 10.1016/j.annepidem.2021.04.009. Epub 2021 Apr 21.
10
Four Aspects Affecting Health Economic Decision Models and Their Validation.影响健康经济决策模型及其验证的四个方面。
Pharmacoeconomics. 2022 Mar;40(3):241-248. doi: 10.1007/s40273-021-01110-w. Epub 2021 Dec 16.

引用本文的文献

1
Implementing Strengths-Based Dialogue to Reframe Clinical Education and Community Engagement.实施基于优势的对话以重塑临床教育与社区参与。
Perspect ASHA Spec Interest Groups. 2023 Oct 12;8(5):1055-1064. doi: 10.1044/2023_PERSP-23-00018. Epub 2023 Aug 25.
2
Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR.提高患者在卫生技术评估中的参与度:利用共识研究克服欧盟卫生技术评估法规下的PICO范围界定挑战
J Mark Access Health Policy. 2025 Jun 2;13(2):27. doi: 10.3390/jmahp13020027. eCollection 2025 Jun.
3
Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.

本文引用的文献

1
A Population-Based Survey of the Workplace Costs for Caregivers of Persons With Treatment-Resistant Depression Compared With Other Health Conditions.一项基于人群的调查显示,与其他健康状况相比,照料治疗抵抗性抑郁症患者的照护者在工作场所的成本更高。
J Occup Environ Med. 2020 Sep;62(9):746-756. doi: 10.1097/JOM.0000000000001957.
2
Social, ethical, and other value judgments in health economics modelling.健康经济学建模中的社会、伦理和其他价值判断。
Soc Sci Med. 2020 May;253:112975. doi: 10.1016/j.socscimed.2020.112975. Epub 2020 Apr 2.
3
Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
加拿大将真实世界证据(RWE)纳入癌症药物资金决策的框架制定:加拿大癌症药物价值真实世界证据(CanREValue)合作项目
BMJ Open. 2025 May 30;15(5):e096286. doi: 10.1136/bmjopen-2024-096286.
4
A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete.评估健康相关生活质量价值集是否过时的分类法。
Pharmacoeconomics. 2025 May;43(5):473-481. doi: 10.1007/s40273-025-01476-1. Epub 2025 Feb 17.
5
Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review.免疫检查点抑制剂作为晚期肝细胞癌一线治疗的成本效益:一项系统评价
Health Econ Rev. 2024 Jul 5;14(1):48. doi: 10.1186/s13561-024-00526-2.
6
Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement.使决策模型适用于特定目的:确保利益相关者参与的重要性。
Pharmacoeconomics. 2024 Mar;42(3):249-252. doi: 10.1007/s40273-023-01348-6. Epub 2024 Jan 18.
7
Values in Modelling: Video Series Development and Evaluation Survey.建模中的价值:视频系列开发与评估调查
Appl Health Econ Health Policy. 2023 Sep;21(5):813-820. doi: 10.1007/s40258-023-00820-w. Epub 2023 Jul 5.
8
Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.司妥昔单抗用于澳大利亚公共投资罕见病特发性多中心Castleman病的成本效益分析
Pharmacoecon Open. 2023 Sep;7(5):777-792. doi: 10.1007/s41669-023-00426-x. Epub 2023 Jun 12.
9
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance.患者和公众参与健康经济学建模提出了规范指导的需求。
Pharmacoeconomics. 2023 Jul;41(7):733-740. doi: 10.1007/s40273-023-01274-7. Epub 2023 Apr 27.
10
Stakeholder Engagement in the Development of Public Health Economic Models: An Application to Modelling of Minimum Unit Pricing of Alcohol in South Africa.利益相关者参与公共卫生经济模型的制定:以南非酒精最低单位定价模型为例。
Appl Health Econ Health Policy. 2023 May;21(3):395-403. doi: 10.1007/s40258-023-00789-6. Epub 2023 Mar 9.
理解美国药品使用中价值的支付方视角。
J Manag Care Spec Pharm. 2019 Dec;25(12):1319-1327. doi: 10.18553/jmcp.2019.25.12.1319.
4
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.卫生经济建模中的透明度:选择、问题及潜在解决方案。
Pharmacoeconomics. 2019 Nov;37(11):1349-1354. doi: 10.1007/s40273-019-00842-0.
5
Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project.开发美国医疗体系的开源模型:开源价值项目的实践经验和当前挑战。
Pharmacoeconomics. 2019 Nov;37(11):1313-1320. doi: 10.1007/s40273-019-00827-z.
6
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.健康经济决策模型中的透明度和验证挑战:来自胡德山的观点。
Pharmacoeconomics. 2019 Nov;37(11):1305-1312. doi: 10.1007/s40273-019-00825-1.
7
Can We Develop Sustainable and Sharable Cost-Effectiveness Models for Value Assessment in the U.S. Health Care System?我们能否为美国医疗保健系统中的价值评估开发可持续和可共享的成本效益模型?
J Manag Care Spec Pharm. 2019 May;25(5):521-524. doi: 10.18553/jmcp.2019.25.5.521.
8
Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.欧盟早期和近期采用者在药品政策中卫生技术评估使用情况的比较。
Value Health Reg Issues. 2018 Sep;16:81-91. doi: 10.1016/j.vhri.2018.08.002. Epub 2018 Oct 11.
9
Value Assessment Frameworks in the United States: A Call for Patient Engagement.美国的价值评估框架:呼吁患者参与
Pharmacoecon Open. 2019 Mar;3(1):1-3. doi: 10.1007/s41669-018-0094-z.
10
An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].价值、视角与决策背景概述——一种卫生经济学方法:ISPOR 特别工作组报告 [2]
Value Health. 2018 Feb;21(2):124-130. doi: 10.1016/j.jval.2017.12.006.